Huanglian Jiedutang Against Acute Ischemic Stroke： A Review
10.13422/j.cnki.syfjx.20260921
- VernacularTitle:黄连解毒汤抗急性缺血性中风研究进展
- Author:
Liyang DONG
1
;
Qinyuan ZHANG
1
;
Yiping WU
1
;
Yingping HE
1
;
Wei SHAO
1
;
Haojia ZHANG
1
;
Xueqian WANG
1
;
Changxiang LI
1
;
Youxiang CUI
2
;
Fafeng CHENG
1
;
Qingguo WANG
1
Author Information
1. School of Traditional Chinese Medicine，Beijing University of Chinese Medicine， Beijing 100029，China
2. Key Laboratory of Integrated Traditional Chinese and Western Medicine for;Neurological Rehabilitation，Cangzhou Hospital of Integrated Traditional Chinese Medicine and;Western Medicine， Cangzhou 061001，China
- Publication Type:Journal Article
- Keywords:
Huanglian Jiedutang;
ischemic stroke;
active ingredient;
clinical application;
experimental research;
multi-target regulation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(11):77-86
- CountryChina
- Language:Chinese
-
Abstract:
Huanglian Jiedutang （HLJDT）， as a classical formula for clearing heat and removing toxins， has been widely applied in the treatment of various clinical diseases in recent years， particularly during the fire-heat stage of stroke， where it has attracted considerable attention. Based on previous studies， this paper systematically elaborates on the research progress on the active components of HLJDT， its clinical application in ischemic stroke， and advances in studies on its mechanisms of action. Modern pharmacological studies have demonstrated that HLJDT contains multiple active components， including baicalin， geniposide， and berberine. In the treatment of ischemic stroke， these components exert therapeutic effects through multi-target， multi-pathway， and multi-level mechanisms. Clinical studies have shown that HLJDT can increase cerebral blood flow， reduce cerebral infarct volume， and improve post-stroke physical dysfunction in patients with ischemic stroke. Experimental studies have indicated that HLJDT can improve neurological function scores and increase cerebral perfusion in experimental stroke models. In addition， the mechanisms underlying the anti-ischemic stroke effects of HLJDT may be related to anti-inflammatory and antioxidant activities， promotion of angiogenesis， and regulation of amino acid and energy metabolism. Although existing studies have confirmed that HLJDT exhibits multi-target and multi-pathway synergistic therapeutic characteristics， further large-sample randomized controlled trials are still needed to verify its long-term efficacy and to further elucidate the dynamic interaction network among components， targets， and pathways. Combined with network pharmacology and molecular docking analyses， this study further clarifies the synergistic targets of the core components （berberine， baicalin， and geniposide）， providing a theoretical basis for in-depth research and clinical translation of HLJDT in the treatment of ischemic stroke.
